Lobe Sciences (LOBE) Stock Price & Analysis
LOBE Stock Chart & Stats
- Day’s Range
- EUR 0.02 - EUR 0.02
- 52-Week Range
- EUR 0.01 - EUR 0.08
- Previous Close
- EUR 0.02
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- EUR 8.89M
- Enterprise Value
- EUR 25.61M
- Total Cash (Recent Filing)
- EUR 5.21M
- Total Debt (Recent Filing)
- EUR 338.40K
- Price to Earnings (P/E)
- ―
- Beta
- 2.48
- Next Earnings
- Dec 18, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Equity Stabilization
The return to positive equity marks a meaningful improvement from the company’s earlier balance-sheet weakness. Although capital remains volatile, this stabilization provides a stronger base for financing, partnerships, and continued development than the negative-equity position reported in prior years.
Modest Absolute Debt
Relatively low absolute debt limits the fixed obligations directly burdening the business and reduces dependence on substantial interest-bearing financing. This offers some financial flexibility while the company works to develop operations, even though shrinking equity makes leverage more significant.
Prior Gross Profit Potential
The strong FY2024 gross-profit share indicates that the company previously demonstrated potentially attractive economics on the revenue it generated. If commercial activity is re-established, that historical margin profile could support operating leverage, although current zero revenue means it is not presently being realized.
Bears Say
No Current Revenue
The absence of current revenue shows that Lobe Sciences does not presently have a functioning commercial revenue base supporting its operations. This weakens visibility into future self-funded growth and leaves successful development, commercialization, or partnering as essential to rebuilding durable earnings capacity.
Worsening Operating Losses
Widening operating losses despite zero revenue indicate that the company continues consuming resources without corresponding commercial output. Persistent losses can erode the capital base, constrain investment in development, and increase the likelihood that future progress requires external financing.
Increasing Cash Burn
Cash generation is materially negative and has deteriorated from the prior fiscal year, demonstrating limited ability to fund operations internally. Continued burn raises financing risk over the medium term and may force the company to prioritize capital preservation over research, development, or commercialization efforts.
Lobe Sciences News
LOBE FAQ
What was Lobe Sciences’s price range in the past 12 months?
What is Lobe Sciences’s market cap?
When is Lobe Sciences’s upcoming earnings report date?
How were Lobe Sciences’s earnings last quarter?
Is Lobe Sciences overvalued?
Does Lobe Sciences pay dividends?
What is Lobe Sciences’s EPS estimate?
How many shares outstanding does Lobe Sciences have?
What happened to Lobe Sciences’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Lobe Sciences?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Lobe Sciences
Lobe Sciences Ltd. operates as a life sciences entity, primarily focused on the exploration and advancement of psychedelic pharmaceutical compounds. The company is actively engaged in formulating psilocybin-derived therapeutics, combined with N-acetylcysteine, intended for the treatment of mild traumatic brain injuries and post-traumatic stress disorder. Beyond drug development, it also engineers specialized devices designed to facilitate the efficient delivery of various medications. The organization was previously known as Greenstar Biosciences Corp. before formally changing its name to Lobe Sciences Ltd. in November 2020. Its main corporate office is situated in Vancouver, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Frederick Dominick Sancilio
- Employees
- 5
- Website
- www.lobesciences.com
- Address
- 1771 Robson Street, Vancouver, BC, V6G 3B7, CA
Lobe Sciences (LOBE) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 5 | 15 |
| Technical Analysis | 2 | 5 | 3 |
| Moving Averages | 0 | 0 | 12 |







